Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?

Bristol Myers Squibb Company (BMY) has regained some of the lost territories in the past month, giving anxious investors a ray of hope. This biotech giant has been facing a few challenges for quite some time now.Shares of BMY have risen 16.4% in a month against the industry’s decline of 0.7%. The stock has also outperformed the sector and the S&P 500 in this period.The rally came after the company reported better-than-expected second-quarter results in July. Upside in blood-thinner drug Eliquis and immuno-o ...